Maravai LifeSciences Holdings, Inc. (MRVI) stock
MRVINasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 7/30170% above fair value
$7.40−0.14 (-1.86%)
Close on Nov 16, 2026Market cap $1.92BP/E –Yield –
Maravai LifeSciences operating margin
Operating margin is operating income as a percentage of revenue.
Maravai LifeSciences's operating margin for the twelve months ending Jun 30, 2026 was -56.1%. For fiscal 2025 it was -115.9%, against -90.9% the year before. The highest annual figure on record is 69.4% in fiscal 2021.
Annual operating margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -115.9% | −25.0 |
| FY2024 | Dec 31, 2024 | -90.9% | −80.0 |
| FY2023 | Dec 31, 2023 | -11.0% | −76.0 |
| FY2022 | Dec 31, 2022 | 65.0% | −4.4 |
| FY2021 | Dec 31, 2021 | 69.4% | +27.2 |
| FY2020 | Dec 31, 2020 | 42.2% | +25.4 |
| FY2019 | Dec 31, 2019 | 16.8% | – |
Quarterly operating margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -29.3% | +110.5 |
| Q1 FY2026 | Mar 31, 2026 | -3.3% | +101.7 |
| Q4 FY2025 | Dec 31, 2025 | -117.9% | −51.2 |
| Q3 FY2025 | Sep 30, 2025 | -98.6% | +141.4 |
| Q2 FY2025 | Jun 30, 2025 | -139.8% | −120.5 |
| Q1 FY2025 | Mar 31, 2025 | -104.9% | −75.5 |
| Q4 FY2024 | Dec 31, 2024 | -66.7% | −57.0 |
| Q3 FY2024 | Sep 30, 2024 | -239.9% | −216.9 |
| Q2 FY2024 | Jun 30, 2024 | -19.4% | −2.5 |
| Q1 FY2024 | Mar 31, 2024 | -29.4% | −32.6 |
| Q4 FY2023 | Dec 31, 2023 | -9.6% | −63.0 |
| Q3 FY2023 | Sep 30, 2023 | -23.1% | −84.2 |
| Q2 FY2023 | Jun 30, 2023 | -16.9% | −91.3 |
| Q1 FY2023 | Mar 31, 2023 | 3.2% | −65.3 |
| Q4 FY2022 | Dec 31, 2022 | 53.4% | −14.3 |
| Q3 FY2022 | Sep 30, 2022 | 61.1% | −14.7 |
| Q2 FY2022 | Jun 30, 2022 | 74.4% | +3.9 |
| Q1 FY2022 | Mar 31, 2022 | 68.5% | +7.0 |
| Q4 FY2021 | Dec 31, 2021 | 67.6% | +35.9 |
| Q3 FY2021 | Sep 30, 2021 | 75.9% | +23.8 |
| Q2 FY2021 | Jun 30, 2021 | 70.5% | +53.2 |
| Q1 FY2021 | Mar 31, 2021 | 61.5% | −6.8 |
| Q4 FY2020 | Dec 31, 2020 | 31.8% | – |
| Q3 FY2020 | Sep 30, 2020 | 52.0% | – |
| Q2 FY2020 | Jun 30, 2020 | 17.3% | – |
| Q1 FY2020 | Mar 31, 2020 | 68.3% | – |
See a number that looks wrong?